New hope for tough breast cancer: experimental drug BFv targets tumors after other treatments fail

NCT ID NCT06908928

Recruiting now Disease control Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called bulumtatug furvedotin (BFv) in 52 people with triple-negative breast cancer that has come back or spread to other parts of the body. Participants must have already received certain types of chemotherapy and antibody-drug conjugates. The main goal is to see if BFv can shrink tumors, and researchers will also track how long any benefit lasts. This is not a cure, but aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Anschutz Medical Center
RECRUITING

Aurora, Colorado, 80045, United States
City of Hope
RECRUITING

Duarte, California, 91010, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
UCSD Moores Cancer Center
RECRUITING

La Jolla, California, 92093, United States
UChicago Medicine Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.